Morphic Holding, Inc. is a pharmaceutical company based in the United States that focuses on developing oral small-molecule integrin therapeutics. With a Risk Rating Score of 27.0, the company is considered to be at medium risk. Integrins are a key focus area for Morphic Holding, with a pipeline of drugs aimed at treating a variety of serious chronic diseases. ESG factors are important to the company's approach to drug development and sustainability.